University of South Florida

Brown University

Saneron Ccel Therapeutics, Inc.

The United States Government As Represented by the Department of Veterans Affairs

Natura Therapeutics, Inc.

Thomas Jefferson University

Targacept, Inc.

Neurotech S.a.

Cryo-cell International, Inc.

Universidade Federal De São Paulo - Unifesp

Medical College of Georgia

Cryopraxis Criobiologia Ltda.

Stemco Biomedical, Inc.

Paul R Sanberg

Patrick Aebischer

Keith E Dionne

Frank T Gentile

Dwaine F Emerich

Orion D Hegre

Michael J Lysaght

Cesario V Borlongan

Alfred V Vasconcellos

Paul E Lacy

Diane Hoffman

Lisa Christenson

David W Scharp

Don F Cameron

Archie A Silver

Jun Tan

Alison Elizabeth Willing

Svitlana Garbuzova-Davis

Douglas Shytle

Mary Newman

Juan Sanchez-Ramos

Roland Douglas Shytle

Daniel D Richard

Paula Cole Bickford

Cyndy Davis Sanberg

Samuel Saporta

Robert W Engelman

William R Gower

Jared Carl Ehrhart

Paul J Mulhauser

Richard M Heller

Nicholas F Warner

Moses Goddard

R Douglas Shytle

Anne M Rathbun

John G Moldauer

Shyam S Mohapatra

Mark Jeffrey Jaroszeski

Subhra Mohapatra

Thomas B Freeman

Shijie Song

Andrew E Balber

Tracy Gentry

Brian Nelson Giunta

Cyndy Davis-Sanberg

Nicole Kuzmin-Nichols

Song Li

Huayan Hou

Sylvia Gografe

Joelle J Hushen

William Janssen

Julie Allickson

David W Sharp

Alfred V Vasooncellos

Agneta Othberg

Alfred V Vasoohcellos

Christian Bernard Brechot

Nelson Americo Hossne, Jr

Stephen Klasko

Judy Genshaft

Adriana Invitti

Nelson Hossne

A method of treating neurodegenerative diseases using hUCB plasma is presented herein. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients. hUCB plasma was shown to increase therapeutic efficacy of MNCs as well as decrease apoptosis of MNCs. The cytokine profile of hUCB plasma supports its usefulness as a sole therapeutic as well as an additive to MNCs.

Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders

A method of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), otherwise known as COVID-19, infection by administering nicotinic receptor antagonists and/or PPAR-&#x3b3; agonists is presented. A combination of mecamylamine, or an isomer thereof, and pioglitazone synergistically reduces replication of SARS-CoV-2 in virus-infected cells and also synergistically reduces inflammatory cytokines such as IL-6, IL-&#x3b2;, and TNF&#x3b1;, which have been associated with SARS-CoV-2 infection.

Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by degeneration of motor neurons in the spinal cord and brain. Increasing evidence shows autoimmune mechanisms likely promote disease progression. Human umbilical cord blood (hUCB) derived plasma is rich in cytokines and growth factors that are required for growth and survival of cells during hematopoiesis. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients.

Blood brain barrier (BBB) permeabilizers, such as mannitol, can facilitate the entry of stem cells from the periphery to the stroke brain. It is unknown whether BBB permeation in the chronic stage of the disease still facilitates the entry of stem cells from the periphery to the injured brain. Evidence herein shows BBB permeation in the chronic stage of stroke assisted in the entry of stem cells from the periphery to the stroke brain. Stroke models treated with human umbilical cord stem cells (hUCBC) only (2 million viable cells), mannitol or a combination. Results revealed that hUCBC alone or combined with mannitol displayed significant behavioral and histological deficits compared to control animals, with the HUCBC-mannitol combined treatment showing improvements over hUCBC only treatments in brain cell survival in the peri-infarct area. BBB permeation in chronic stroke also lowers the effective stem cell dose necessary to improve functional outcomes.

Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers

The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina.

Ischemic tissue cell therapy

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depressoin, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

Exo-S-mecamylamine formulation and use in treatment

A combined therapy of human umbilical cord blood cells (hUCB) and G-CSF at the acute stage of TBI was tested as a therapeutic for progressive secondary effects of chronic TBI. Rats were treated with saline carrier, or therapeutic in carrier as follows; G-CSF, hUCB, or hUCB and G-CSF, 7-days after TBI. Eight weeks later, behavioral testing was performed and brains harvested to analyze hippocampal cell loss, neuroinflammatory response, and neurogenesis. Results revealed that the monotherapies partially suppressed neuroinflammation and reduced hippocampal cell loss. However, combined therapy of hUCB and G-CSF robustly dampened neuroinflammation, while enhancing endogenous neurogenesis and reducing hippocampal cell loss. Vigorous and long-lasting recovery of motor function accompanied the combined therapy, which was either moderately or short-lived in the monotherapy conditions. These results suggest that combined treatment rather than monotherapy appears optimal for abrogating histophalogical and motor impairments in chronic TBI.

Combination therapy of stem cell mobilizing agents and stem cell transplantation

Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, A&#x3b2; phagocytic activity was increased and soluble and insoluble A&#x3b2; protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of A&#x3b2;peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.

HUCBC treatment of amyloid-associated disease

The present invention provides fusion peptides, compositions, methods and kits for treating, reducing the risk of, lessening the severity of, preventing, or delaying the onset of amyloid-related disorders, such as Alzheimer's disease and HIV associated neurocognitive impairment.

Amyloid precursor protein (APP) based &#xc3;#-secretase inhibitor peptides, and methods of use

Provided herein are compositions, formulations, kits, and methods for improving or modifying cognitive performance in an individual having normal-age related cognitive decline. The composition can include an amount of a blueberry extract, L-carnosine, a green tea extract, vitamin D, and a grape extract. The composition can be included in a pharmaceutical formulation and be administered to a subject having normal-age related cognitive decline according to a dosing regimen.

Compositions and methods of improving cognitive performance

The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.

Human cord blood as a source of neural tissue repair of the brain and spinal cord

Wiper blade ornament

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

Growing community of inventors

Tampa, FL, United States of America

Paul R Sanberg